Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Biocad
- Target Recruit Count
- 366
- Registration Number
- NCT05986331
- Locations
- 🇷🇺
Budgetary healthcare institution of the Omsk region "Clinical oncological dispensary", Omsk, Russian Federation
🇷🇺"Saint Petersburg Clinical Research and Practice Center for Specialized Medical Care (Oncology)", Saint Petersburg, Russian Federation
🇷🇺Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State University", Saint Petersburg, Russian Federation
A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 146
- Registration Number
- NCT05974969
- Locations
- 🇷🇺
Institute of the Human Brain n. a. N.P. Bekhtereva Russian Academy of Sciences, Saint Petersburg, Russian Federation
🇷🇺Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation
🇷🇺X7 Clinical Research, Saint Petersburg, Russian Federation
Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Biocad
- Target Recruit Count
- 374
- Registration Number
- NCT05802225
- Locations
- 🇷🇺
Budgetary healthcare institution of the Omsk region "Clinical oncological dispensary", Omsk, Russian Federation
🇷🇺The Loginov Moscow Clinical Scientific Center MHD, Moscow, Russian Federation
🇷🇺JSC "Modern Medical Technologies", Saint Petersburg, Russian Federation
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Biocad
- Target Recruit Count
- 261
- Registration Number
- NCT05800327
- Locations
- 🇷🇺
X7 Clinical Research, Saint Petersburg, Russian Federation
Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Biocad
- Target Recruit Count
- 114
- Registration Number
- NCT05783882
- Locations
- 🇷🇺
N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
🇷🇺State Budgetary Institution of Healthcare "Clinical Oncology Dispensary of Chelyabinsk Region" (SBIH CODCR), Cheliabinsk, Russian Federation
🇷🇺State Budgetary Institution of Healthcare of the Arkhangelsk Region "Arkhangelsk Regional Clinical Oncology Dispensary" (SBHI AR ARCOD), Arkhangel'sk, Russian Federation
Phase 1 Study of BCD-245 in Subjects With Neuroblastoma
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Biocad
- Target Recruit Count
- 24
- Registration Number
- NCT05782959
- Locations
- 🇷🇺
Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
🇷🇺Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
🇷🇺Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg, Russian Federation
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Biocad
- Target Recruit Count
- 410
- Registration Number
- NCT05751928
- Locations
- 🇧🇾
Healthcare Institution "Minsk City Clinical Cancer Center", Minsk, Belarus
🇧🇾Healthcare Institution "Vitebsk Regional Clinical Oncology Center", Vitebsk, Belarus
🇧🇾State Institution "Republican Scientific and Practical Center of Oncology and Medical Radiology named after A.I. N.N. Alexandrov", Lesnoy, Belarus
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Biocad
- Target Recruit Count
- 40
- Registration Number
- NCT05747261
- Locations
- 🇧🇾
1. State Institution Republican Scientific and Practical Center "Mother and Child", Minsk, Belarus
🇷🇺Federal State Budgetary Institution "V. A. Almazov National Medical Research Center" of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation
🇷🇺Federal State Autonomous Institution "National Medical Research Center for Children's Health", Ministry of Health of the Russian Federation, Moscow, Russian Federation
Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Biocad
- Target Recruit Count
- 131
- Registration Number
- NCT05739006
- Locations
- 🇷🇺
Budgetary healthcare institution of the Omsk region "Clinical oncological dispensary", Omsk, Russian Federation
🇷🇺State Budgetary Healthcare Institution "Saint Petersburg Clinical Research and Practice Center for Specialized Medical Care (Oncology)", Saint Petersburg, Russian Federation
🇷🇺"Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Biocad
- Target Recruit Count
- 100
- Registration Number
- NCT05738993
- Locations
- 🇷🇺
City Polyclinic №77, Saint Petersburg, Russian Federation
🇷🇺X7 Clinical Research, Saint Petersburg, Russian Federation